BME100 f2015:Group1 1030amL2

From OpenWetWare
Jump to: navigation, search
Owwnotebook icon.png BME 100 Fall 2015 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
BME494 Asu logo.png


OUR TEAM

Name: Nichole Torgerson
Name: Alarmel Sira
Name: Matt Chrest
Name: Lindsey O'Brien
Name: Jacob Aperi
Name: Michael "Otis" Clyne

LAB 2 WRITE-UP

Descriptive Statistics

Experiment 1 - Human Trial

Dosages 0mg 5mg 10mg 15mg
Average 3.834 8.932 61.622 657.941
Standard Deviation 1.52301 1.593932 30.11069 212.943
Standard Error 0.50767 0.531311 10.0369 70.98099

Experiment 2 - Rat Trial

Dosages 0mg 10mg
Average 10.516 11.112
Standard Deviation 2.225552 7.402886
Standard Error 0.995297 3.310671




Results

Experiment 1 - Human Trial

Average Change in Inflammotin Due to LPS Dosage


Experiment 2 - Rat Trial

Average Change in Inflammotin Due to LPS Dosage




Analysis

Experiment 1-Human Trial

The graphs show there is significant difference between the dosages. This means that the increase in dosage of Inflammotin increases the inflammation in elderly humans. The LPS has a positive correlation with Inflammotin levels.

Experiment 2-Rat Trial

The graphs show there is no significance between dosages. The increase in dosages do not have an effect on the Inflammation levels, therefore there is no correlation between the two.



Summary/Discussion

When the two experiments were formed, there was an effect on elderly people in increasing the dosages, but there was no effect on the rats when the dosages were increased. A reason there is an effect in humans is only because they have a better response to the Inflammotin where the rats do not have as good of a response. Another reason is because only humans have the protein in their body, that causes a change in inflammation.